Clinical Trial

Bioequivalence Study of BGM0504 Injection

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 3, 2026 (before its estimated February 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference formula R).
Trial Details
NCT Number NCT07382908
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Collaborators: BrightGene Pharmaceutical Co., Ltd.
Conditions Overweight/Obesity
Enrollment 144 participants
Start Date 2025-12-23
Primary Completion 2026-02-12 (estimated)
Study Completion 2026-02-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-03